Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCCAmezalpat builds momentum with both ...

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

The firm will study its autologous cell therapy alone and in combination with Eisai's Lenvima in patients with hepatitis B-driven hepatocellular carcinoma.

The FDA has granted fast track designation to amezalpat for the treatment of patients with hepatocellular carcinoma.

Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.

Hundreds of a people who have chronic liver disease are being helped by an NHS trust's service that helps them attend vital ...

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.

CAR T-cell therapies have demonstrated efficacy in treating blood cancers but, so far, their safety and effectiveness in ...

New model predicts HCC risk in noncirrhotic chronic hepatitis B patients, improving early detection strategies.

Hepatobiliary cancers, which include biliary tract cancer (BTC) and hepatocellular carcinoma (HCC), are among the most lethal ...

“The casdozo data in HCC demonstrate translation of the preclinical ... deaths from liver cancer and intrahepatic bile duct cancer in the US; estimates of future enrollment in Coherus ...